Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZIVO Bioscience, Inc. (ZIVO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly reports and other documents filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with a Commission File Number of 000-30415, ZIVO uses these filings to report material events, describe its business and update investors on governance and financial matters.
For a research and development company like ZIVO, SEC filings are a key source of information on its biotech and agtech activities involving proprietary algal and bacterial strains, biologically active molecules and complexes, and related intellectual property. Filings can explain how the company characterizes its focus on human and animal health applications, outline risk factors and summarize relationships with collaborators and counterparties.
Current reports on Form 8-K, such as the filing describing the resignation of a Chief Financial Officer and the appointment of an Interim Chief Financial Officer under an independent contractor services agreement, document significant management changes and associated compensation arrangements. Investors can also use this page to monitor future 10-K annual reports and 10-Q quarterly reports for updates on ZIVO’s R&D programs, liquidity, and any disclosed licensing or collaboration agreements.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in plain language, helping readers quickly understand lengthy documents. Real-time updates from EDGAR ensure that new ZIVO filings appear promptly, while access to ownership and insider transaction reports, such as Form 4 when filed, allows users to track equity-related activity by directors and officers. This combination of raw filings and AI analysis offers a structured way to review ZIVO’s regulatory history and ongoing disclosure record.
ZIVO Bioscience (ZIVO) filed its Q3 2025 10‑Q, showing modest revenue growth alongside tight liquidity and continued losses. Revenue was $65,625, up from $31,500, with gross margin of $21,288. The company reported a net loss of $1,033,056 for the quarter and operating cash outflow of $2,173,204 for the nine months.
Cash declined to $57,222 with total liabilities of $3,846,055 and a stockholders’ deficit of $(3,286,603). Shares outstanding were 3,832,327 as of September 30, 2025, and 3,888,595 as of November 9, 2025. Management states there is substantial doubt about the ability to continue as a going concern and estimates needing about $6.0 million over the next 12 months to fund basic operations.
During 2025, ZIVO raised funds via private equity and debt, including a $250,000 convertible note at 10% with warrants to purchase 1,793 shares at $13.94. Subsequent to quarter‑end (October 2025), the company sold 54,168 shares and 3,091 warrants, raising $390,000 in cash and exchanging $284,433 of related party payables. Material weaknesses in internal control over financial reporting persist.
Zivo Bioscience (ZIVO): Insider transaction reported. Affiliates of Strome Group reported a purchase of Zivo Bioscience common stock and warrants on 10/13/2025. The filing shows a purchase of 20,259 shares of common stock at $12.34 per share, held indirectly by an entity.
The report also lists acquisition of 2,025 Common Stock Purchase Warrants with an exercise price of $12.34, exercisable on 10/13/2025 and expiring on 10/12/2030. Following these transactions, the filing shows 452,942 common shares and 43,071 derivative securities beneficially owned indirectly by the reporting entity. The securities were acquired pursuant to a Securities Purchase Agreement.
Zivo Bioscience (ZIVO) reported an insider purchase. Director and 10% owner Laith L. Yaldoo acquired 1,659 shares of common stock on 10/10/2025 at $12.05 per share, held indirectly through HEP Investments LLC. Following the trade, beneficial ownership was 575,095 shares, reported as indirect.
Christopher D. Maggiore, a director and reported >10% owner of Zivo Bioscience, Inc. (ZIVO), purchased 23,682 shares of the companys common stock on
Zivo Bioscience (ZIVO) reported an insider equity award. On 10/02/2025, a reporting person who is a Director and 10% Owner received 926 nonstatutory stock options to buy common stock at an exercise price of $12.03 per share, expiring on 10/02/2035. The filing notes the option grant was issued under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $9,452.05. Ownership of these derivative securities is listed as Direct (D).
Zivo Bioscience, Inc. (ZIVO) director and 10% owner Christopher D. Maggiore was granted 1,075 nonstatutory stock options on
Zivo Bioscience, Inc. (ZIVO) director Alison Cornell received a grant of This transaction increases the reporting person’s direct beneficial ownership by
Laith Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), reported a purchase of 15,322 shares of the company's common stock on 09/30/2025 at a price of $15.99 per share. After the transaction, the filing shows beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC. The Form 4 was signed on 10/02/2025.
This report documents an insider acquisition, increasing the reporting person's indirect stake via an investment vehicle. The filing does not disclose any derivative transactions or additional context for the purchase beyond the amounts, price, and ownership form.